Watch More Highlights
Oxana Megherea, PharmD, BCOP, of Penn Medicine, University of Pennsylvania Health System, discusses results of a phase III study showing that progression-free survival with ibrutinib plus obinutuzumab plus venetoclax (IVO) is not superior to ibrutinib plus obinutuzumab (IO) for treatment-naive older patients with chronic lymphocytic leukemia in the setting of the COVID-19 pandemic. Long-term follow-up will determine whether there are advantages to IVO, with special attention to measurable residual disease and therapy discontinuation (Abstract 7500).